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Ibrutinib in Combination with Sorafenib Synergistically Inhibits 
Proliferation and Survival of Hepatocellular Carcinoma Cells by Targeting 
EGFR Signaling Pathway   
Cho-Hao Lin, Nissar Wani, Khadija Elkholy, Kalpana Ghoshal 
 
Hepatocellular carcinoma (HCC) is the second major cause of cancer-related 
death worldwide with limit therapeutic options. Thus, there is an urgent need to 
develop novel alternative therapies for HCC. In this study, we report that 
ibrutinib, recently approved for CLL and MCL therapies, and a covalent 
inhibitor of TEC (BTK, ITK etc.) and ERBB (EGFR, Her2 etc.) family of tyrosine 
kinases, inhibits tumorigenic functions of human and mouse HCC cells in cell 
culture and in HCC xenografts. More importantly, co-treatment with ibrutinib 
and sorafenib, an approved targeted therapy for advanced HCCs that 
marginally improve patients’ survival, induced HCC cell apoptosis, and 
synergistically inhibited HCC cell proliferation including sorafenib-resistant 
cells. Besides, HCC spheroid formation and expression of cancer stem cell 
markers were suppressed by ibrutinib and sorafenib co-treatment. This 
combination therapy significantly suppressed the increase in tumor volume 
and weight of highly aggressive HCCLM3 subcutaneous xenografts in NSG 
mice. In addition, we show that ibrutinib inhibited ERK and Akt signaling 
pathways through inactivating EGFR, its irreversible substrate, and its 
downstream Akt and ERK signaling in HCC cells. Knocking down EGFR 
expression reduced sensitivity of HCC cells to ibrutinib. The constitutively 
active Akt signaling abrogated the synergism of two agents on inhibiting HCC 
cell proliferation, suggesting that Akt signaling is critical for mediating the 
synergistic effect of these two kinase inhibitors. Collectively, this study 
indicates that ibrutinib could be a re-purposed anti-HCC drug, and our data 
provides the evidence for the therapeutic potential of ibrutinib and sorafenib 
combination as an effective and attractive strategy for treating HCCs including 
those with sorafenib resistance. 
 
